Evidence map›Paper›PMID 12560336›Full record

ArticleThe Journal of biological chemistry2003

Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides.

Nino Mzhavia, Hui Pan, Fa-Yun Che, Lloyd D Fricker, Lakshmi A Devi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Endothelin-converting enzyme 2 regulates κ opioid receptor trafficking and function.The Journal of pharmacology and experimental therapeutics · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Neprilysin Inhibitors and Bradykinin.Frontiers in medicine · 2018
    Review
  13. Endothelin.Pharmacological reviews · 2016
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nino MzhaviaDepartment of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, New York 10029, USA.
Hui Pan
Fa-Yun Che
Lloyd D Fricker
Lakshmi A Devi
Icahn School of Medicine at Mount Sinai · USAlbert Einstein College of Medicine · US

Funding

Enzymes Involved in Neuropeptide Biosynthesis, Processing and RegulationR01NS026880 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEVI, LAKSHMI A · 1994 to 2019
$6.5M
REGULATION OF ENKEPHALIN CONVERTASE--CARBOXYPEPTIDASE ER01DA004494 · NIDA · YESHIVA UNIVERSITY · PI FRICKER, LLOYD D · 1987 to 2015
$5.9M
POST-TRANSLATIONAL REGULATION OF OPIOID RECEPTORSK02DA000458 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEVI, LAKSHMI A · 2000 to 2004
$539k
ENZYMES INVOLVED IN DYNORPHIN BIOSYNTHESISR29NS026880 · NINDS · NEW YORK UNIVERSITY · PI DEVI, LAKSHMI A · 1989 to 1993
–
NIDA NIH HHS DA00458NIDA NIH HHS DA 04494NIDA NIH HHS K02 DA000458NIDA NIH HHS R01 DA004494NINDS NIH HHS NS 26880NINDS NIH HHS R01 NS026880
6 · The paper itself

Abstract

Most neuroendocrine peptides are generated by proteolysis of the precursors at basic residue cleavage sites. Prohormone convertases belonging to the subtilisin family of serine proteases are primarily responsible for processing at these "classical sites." In addition to the classical cleavages, a subset of bioactive peptides is generated by processing at "nonclassical" sites. The proteases responsible for these cleavages have not been well explored. Members of several metalloprotease families have been proposed to be involved in nonclassical processing. Among them, endothelin-converting enzyme-2 (ECE-2) is a good candidate because it exhibits a neuroendocrine distribution and an acidic pH optimum. To examine the involvement of this protease in neuropeptide processing, we purified the recombinant enzyme and characterized its catalytic activity. Purified ECE-2 efficiently processes big endothelin-1 to endothelin-1 by cleavage between Trp(21) and Val(22) at acidic pH. To characterize the substrate specificity of ECE-2, we used mass spectrometry with a panel of 42 peptides as substrates to identify the products. Only 10 of these 42 peptides were processed by ECE-2. A comparison of residues around the cleavage site revealed that ECE-2 exhibits a unique cleavage site selectivity that is related to but distinct from that of ECE-1. ECE-2 tolerates a wide range of amino acids in the P1-position and prefers aliphatic/aromatic residues in the P1'-position. However, only a small fraction of the aliphatic/aromatic amino acid-containing sites were cleaved, indicating that there are additional constraints beyond the P1- and P1'-positions. The enzyme is able to generate a number of biologically active peptides from peptide intermediates, suggesting an important role for this enzyme in the biosynthesis of regulatory peptides. Also, ECE-2 processes proenkephalin-derived bovine adrenal medulla peptides, and this processing leads to peptide products known to have differential receptor selectivity. Finally, ECE-2 processes PEN-LEN, an endogenous inhibitor of prohormone convertase 1, into products that do not inhibit the enzyme. Taken together, these results are consistent with an important role for ECE-2 in the processing of regulatory peptides at nonclassical sites.

Indexed as

Amino Acid SequenceAnimalsAspartic Acid EndopeptidasesCatalytic DomainCations, DivalentCloning, MolecularEndothelin-Converting EnzymesHydrogen-Ion ConcentrationHydrolysisKineticsMetalloendopeptidasesPeptidesRatsSolubilityAspartic Acid EndopeptidasesCations, DivalentEndothelin-Converting EnzymesMetalloendopeptidasesPeptides

Identifiers

PMID12560336
PMCPMC3862352
OpenAlexW1971039109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.